PE2 Prime Editor Nuclease
Product Introduction
PE2 (Prime Editor 2) is the core component of the revolutionary prime editing system. It is a fusion protein consisting of a SpCas9(H840A) nickase and an optimized Moloney Murine Leukemia Virus reverse transcriptase (M-MLV RT), enabling precise gene editing without the need for DNA double-strand breaks. The Cas9 moiety of this protein carries the H840A point mutation, which specifically inactivates the HNH nuclease domain while retaining RuvC activity. Consequently, it cleaves only the non-target strand of DNA (the strand not complementary to the sgRNA), generating a precise single-strand nick. The fused M-MLV reverse transcriptase has been optimized through five key amino acid substitutions, significantly enhancing its thermostability, processivity, and template binding affinity.
This system can perform all 12 types of single-base substitutions, as well as the precise insertion or deletion of small DNA fragments. The entire process neither requires the generation of hazardous DNA double-strand breaks nor relies on exogenous donor DNA templates, significantly reducing the risk of off-target effects and the potential for chromosomal rearrangements. Compared to the first-generation PE1, the editing efficiency of PE2 is increased by 2.3- to 5.1-fold through protein engineering optimization of the reverse transcriptase, laying an important foundation for the widespread application of prime editing technology in basic research, gene therapy, and crop breeding.
Product Specifications
Parameter | Specification |
Source | Recombinant expression in E. coli |
Molecular Weight | ~172 kDa |
Concentration | 20 μM |
PAM Sequence | 5'-NGG-3' |
Mutation Site | H840A |
Domain | M-MLV RTase |
Purity | ≥95% (SDS-PAGE) |
Endotoxin | <1 EU/μg |
Storage Buffer | 50 mM Tris-HCl, 150 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1% NP-40, 50% Glycerol |
10× Reaction Buffer | 500 mM Tris-HCl, 750 mM KCl, 30 mM MgCl₂, 100 mM DTT, pH 8.3 |
Storage Conditions | Long-term storage at -80°C; short-term storage at -20°C |
Product Specifications
Specifications | Catalog Number | Concentration | Volume |
100 pmol | GR100601 | 20 μM | 5 μL |
500 pmol | GR100602 | 20 μM | 25 μL |
2500 pmol | GR100603 | 20 μM | 125 μL |
Application Scenarios
Precise point mutation correction: Correcting pathogenic single nucleotide variants.
Small fragment insertions: Inserting small tag sequences or regulatory elements.
Precise deletions: Removing small harmful DNA sequences.
Disease modeling: Precisely introducing disease-associated mutations.
Functional studies: Investigating the biological effects of specific mutations.
Preclinical gene therapy research: Preclinical studies for correcting genetic diseases.
References
Anzalone AV, et al. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 576(7785):149-157.
Chen PJ, et al. (2021). Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 184(22):5635-5652.